Olaf Heidenreich

List of Publications by Year
in descending order

159 papers	7,132 citations	70961 41 h-index	62479 80 g-index
177 all docs	177 docs citations	177 times ranked	8761 citing authors

#	Article	IF	Citations
1	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 2022, 139, 1080-1097.	0.6	16
2	Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia. Nature Medicine, 2022, 28, 743-751.	15.2	35
3	Elucidating miRNA Function in Cancer Biology via the Molecular Geneticsâ€™ Toolbox. Biomedicines, 2022, 10, 915.	1.4	4
4	A robust post-insertion method for the preparation of targeted siRNA LNPs. International Journal of Pharmaceutics, 2022, 620, 121741.	2.6	8
5	RUNX1/ETO effects on the interactions with t(8;21) AML with bone marrow niche: lessons from scRNAseq. Klinische Padiatrie, 2022, , .	0.2	0
6	Direct targeted therapy for MLLâ€fusionâ€driven highâ€risk acute leukaemias. Clinical and Translational Medicine, 2022, 12, .	1.7	5
7	Efficient Expansion of Immature Acute Myeloid Leukaemia Cells in an Ex Vivo Co-culture System. Klinische Padiatrie, 2022, , .	0.2	0
8	Epigenetic modifiers direct lineage switch in MLL-AF4 leukemia. Klinische Padiatrie, 2022, , .	0.2	0
9	Targeting the unique barcode of MLL/AF4. Klinische Padiatrie, 2022, , .	0.2	0
10	Silencing the leukaemic fusion gene RUNX1/ETO by siRNA-loaded lipid nanoparticles restores myeloid differentiation. Klinische Padiatrie, 2022, , .	0.2	0
11	Deep learning-based cell segmentation identifies T cell infiltration and spatial distribution in de novo pediatric AML. Klinische Padiatrie, 2022, , .	0.2	0
12	Ex vivo and in vivo complex drug combination analysis for improved efficacy and specificity in high-risk childhood acute lymphoblastic leukaemia. Klinische Padiatrie, 2022, , .	0.2	0
13	Understanding the FLT3-ITD maintenance and relapse pathways by RNAi screens. Klinische Padiatrie, 2022, , .	0.2	0
14	Characterizing alternative splicing landscape by RUNX1/ETO reveals novel vulnerabilities in t(8;21) leukemia. Klinische Padiatrie, 2022, , .	0.2	0
15	Epigenetic regulator genes direct lineage switching inÂMLL/AF4 leukemia. Blood, 2022, 140, 1875-1890.	0.6	26
16	H3K79me2/3 controls enhancerâ€“promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Leukemia, 2021, 35, 90-106.	3.3	35
17	The RUNX1/RUNX1T1 network: translating insights into therapeutic options. Experimental Hematology, 2021, 94, 1-10.	0.2	16
18	Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell Reports, 2021, 35, 109010.	2.9	12

#	Article	IF	Citations
19	Venetoclax and dexamethasone synergize with inotuzumab ozogamicinâ€“induced DNA damage signaling in B-lineage ALL. Blood, 2021, 137, 2657-2661.	0.6	15
20	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. Cancers, 2021, 13, 4364.	1.7	5
21	RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia. Nature Communications, 2021, 12, 520.	5.8	27
22	To switch or not to switch: PU.1 expression is the question. Blood, 2021, 138, 1289-1291.	0.6	1
23	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
24	The EHA Research Roadmap: Normal Hematopoiesis. HemaSphere, 2021, 5, e669.	1.2	1
25	t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming. Cells, 2020, 9, 2681.	1.8	5
26	Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model. Molecular Cancer Research, 2020, 18, 1603-1612.	1.5	1
27	Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1â€'RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells. Oncology Reports, 2019, 41, 2027-2040.	1.2	9
28	Targeting the thioredoxin system as a novel strategy against Bâ€cell acute lymphoblastic leukemia. Molecular Oncology, 2019, 13, 1180-1195.	2.1	24
29	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS ONE, 2019, 14, e0225977.	1.1	4
30	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia, 2019, 33, 1313-1323.	3.3	20
31	Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nature Genetics, 2019, 51, 151-162.	9.4	140
32	The SF3b Splicing Complex Regulates DNA Damage Response in Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1237-1237.	0.6	5
33	Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia. Blood, 2019, 134, 113-113.	0.6	1
34	Whole-Genome CRISPR Screen Reveals the Mechanism of Relapse in Patient-Derived Cells Representing High-Risk Paediatric ALL. Blood, 2019, 134, 3952-3952.	0.6	0
35	Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal. Blood, 2019, 134, 531-531.	0.6	0
36	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica, 2018, 103, 634-644.	1.7	13

#	Article	IF	Citations
37	Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1379-1389.	1.3	85
38	The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis. Leukemia, 2018, 32, 323-331.	3.3	50
39	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	3.3	527
40	The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell, 2018, 34, 626-642.e8.	7.7	81
41	Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. Blood Advances, 2018, 2, 1157-1169.	2.5	28
42	Redeployed drug inducing MLL fusion degradation. Klinische Padiatrie, 2018, 230, .	0.2	0
43	Therapeutic targeting of the leukaemic fusion gene RUNX1/ETO. Klinische Padiatrie, 2018, 230, .	0.2	1
44	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. Blood, 2018, 132, 4025-4025.	0.6	0
45	MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. Cell Reports, 2017, 18, 482-495.	2.9	69
46	Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia, 2017, 31, 2577-2586.	3.3	31
47	RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML. Cell Reports, 2017, 19, 1654-1668.	2.9	46
48	Identification of common and distinct epigenetic reprogramming properties of RUNX1 fusion proteins in acute myeloid leukaemia. Lancet, The, 2017, 389, S63.	6.3	0
49	Dormancy Stems the Tide of Chemotherapy. Cancer Cell, 2016, 30, 825-826.	7.7	12
50	BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Leukemia, 2016, 30, 1920-1923.	3.3	17
51	Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia. Leukemia, 2016, 30, 1691-1700.	3.3	44
52	The ability to cross the bloodâ€“cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood, 2016, 127, 1998-2006.	0.6	66
53	UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia, 2016, 30, 728-739.	3.3	45
54	The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype. Leukemia, 2016, 30, 251-254.	3.3	23

#	Article	IF	Citations
55	Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation. Blood, 2016, 128, 835-835.	0.6	2
56	Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model. Blood, 2016, 128, 4031-4031.	0.6	0
57	Gene Silencing by RNAi in Mammalian Cells. Current Protocols in Molecular Biology, 2015, 111, 26.2.1-26.2.17.	2.9	5
58	Genomics and drug profiling of fatal TCF3-HLFâˆ’positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	9.4	190
59	The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia, 2015, 29, 1623-1631.	3.3	34
60	CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015, 62, 1144-1148.	0.8	23
61	A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP-ALL Implicates the Transcription Factors FOXO3 and PRDM1. Blood, 2015, 126, 2449-2449.	0.6	0
62	A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse. Blood, 2015, 126, 2619-2619.	0.6	0
63	High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity. Blood, 2015, 126, 844-844.	0.6	0
64	Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging. PLoS ONE, 2014, 9, e85128.	1.1	36
65	Differential expression of miR-17â^¼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia, 2014, 28, 554-565.	3.3	54
66	Pontin is a critical regulator for AML1-ETO-induced leukemia. Leukemia, 2014, 28, 1271-1279.	3.3	39
67	Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal. Cell Reports, 2014, 8, 1974-1988.	2.9	106
68	Preclinical modelling of childhood acute lymphoblastic leukaemia. Lancet, The, 2014, 383, S27.	6.3	0
69	Abstract 2057: The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy. , 2014, , .		0
70	Identification of a Dynamic Core Transcriptional Network in t(8;21) AML Regulating Differentiation Block and Self-Renewal. Blood, 2014, 124, 1061-1061.	0.6	0
71	Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing. Blood, 2014, 124, 5501-5501.	0.6	0
72	A Genome-Wide RNAi Screen to Identify Novel Genes Involved in Clonal Maintenance of ALL. Blood, 2014, 124, 2390-2390.	0.6	0

#	Article	IF	Citations
73	Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia, 2013, 27, 718-721.	3.3	30
74	Acute B lymphoblastic leukaemiaâ€propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine, 2013, 5, 38-51.	3.3	80
75	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	3.3	393
76	Determination of key structureâ€“activity relationships in siRNA delivery with a mixed micelle system. Journal of Controlled Release, 2013, 172, 939-945.	4.8	27
77	Identification of a dynamic core transcriptional regulatory network for t(8;21) AML. Experimental Hematology, 2013, 41, S16.	0.2	0
78	Molecular Parameters of siRNAâ€“Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery. ACS Nano, 2013, 7, 3797-3807.	7.3	135
79	Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression. Blood, 2013, 122, 759-769.	0.6	23
80	The Genomic Landscape Of Lineage Switch Acute Leukemia. Blood, 2013, 122, 2552-2552.	0.6	2
81	Abstract 3921: The use of a novelin vivoorthotopic imaging model of AML for assessment of drug efficacy.. , 2013, , .		0
82	Clonal Progression Including Evolution Of An iAMP21 Chromosome In Xenograft Models Of BCP-ALL. Blood, 2013, 122, 2485-2485.	0.6	0
83	Mirâ¼17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 835-835.	0.6	0
84	AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia. Leukemia, 2012, 26, 1131-1135.	3.3	10
85	Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia, 2012, 26, 1829-1841.	3.3	161
86	Effective and specific control of aml1/eto gene expression in acute myeloid leukemia cells by lentivector-based RNA-interference. Molecular Biology, 2011, 45, 300-308.	0.4	1
87	The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene, 2011, 30, 3062-3072.	2.6	45
88	The Angiogenic Factor Angiopoietin-1 Is Regulated by the Acute Myeloid Leukemia Fusion Protein AML1/ETO. Blood, 2011, 118, 2426-2426.	0.6	0
89	Significance of Fusion Genes for Maintenance of Leukaemia. Blood, 2011, 118, 2455-2455.	0.6	0
90	Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. Journal of Controlled Release, 2010, 144, 251-258.	4.8	53

#	Article	IF	Citations
91	Proliferation of human primary vascular smooth muscle cells depends on serum response factor. European Journal of Cell Biology, 2010, 89, 216-224.	1.6	41
92	Understanding the cancer stem cell. British Journal of Cancer, 2010, 103, 439-445.	2.9	181
93	Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia, 2010, 24, 1751-1759.	3.3	39
94	AML1/ETO Proteins Control POU4F1/BRN3A Expression and Function in t(8;21) Acute Myeloid Leukemia. Cancer Research, 2010, 70, 3985-3995.	0.4	17
95	Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6. Biochimie, 2010, 92, 455-463.	1.3	34
96	EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis, 2010, 209, 51-57.	0.4	110
97	In Acute Lymphoblastic Leukaemia, Stemness Is Frequent and Ubiquitous. Blood, 2010, 116, 92-92.	0.6	1
98	A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12043-12048.	3.3	46
99	Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo. Leukemia, 2009, 23, 188-190.	3.3	20
100	A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia, 2009, 23, 614-617.	3.3	56
101	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	3.3	363
102	Targeting Oncogenes with siRNAs. Methods in Molecular Biology, 2009, 487, 1-22.	0.4	9
103	Graft Protection in Bypass Surgery: siRNA-Mediated Silencing of Adhesion Molecules. Oligonucleotides, 2009, 19, 15-22.	2.7	9
104	Malignant stem cells in childhood ALL: the debate continues!. Blood, 2009, 113, 4476-4477.	0.6	11
105	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 2009, 114, 2688-2698.	0.6	445
106	Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica, 2008, 93, 1728-1733.	1.7	27
107	IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). Blood, 2008, 112, 787-787.	0.6	2
108	The T(4;11) Fusion Protein MLL/AF4 Regulates TERT Expression. Blood, 2008, 112, 3111-3111.	0.6	0

#	Article	IF	Citations
109	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. Journal of Cellular and Molecular Medicine, 2007, 11, 139-147.	1.6	23
110	Epigenetic Repression of the Adaptor Molecule LAT2 by the Leukemic Fusion Protein AML1/ETO.. Blood, 2007, 110, 987-987.	0.6	0
111	RNA Interference in Haematopoietic and Leukaemic Cells. , 2007, , 29-48.		0
112	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. Journal of Cellular and Molecular Medicine, 2006, 10, 880-889.	1.6	0
113	Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials1. Acta Pharmacologica Sinica, 2006, 27, 273-281.	2.8	28
114	siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene, 2006, 25, 6067-6078.	2.6	65
115	Potential applications of small interferring RNA in the cardiovascular field. Drugs of the Future, 2006, 31, 513.	0.0	14
116	Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. Journal of Cellular and Molecular Medicine, 2006, 10, 1-9.	1.6	0
117	Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood, 2005, 106, 3559-3566.	0.6	81
118	Suppression of ICAM-1 in human venous endothelial cells by small interfering RNAs. European Journal of Cardio-thoracic Surgery, 2005, 28, 816-820.	0.6	21
119	Depletion of the Leukemic Fusion Protein MLL-AF4 with Short Interfering RNAs (siRNAs) Affects Post-Translational Modification of Aldolase A.. Blood, 2005, 106, 4341-4341.	0.6	0
120	Targeting MLL-AF4 with Short Interfering RNAs (siRNAs) Induces Apoptosis Related Genes APAF-1 and SEPT4 in t(4;11)-Positive Human Leukemic Cells.. Blood, 2005, 106, 2606-2606.	0.6	0
121	The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer, 2004, 4, 44.	1.1	49
122	RNA interference as a potential tool in the treatment of leukaemia. Expert Opinion on Biological Therapy, 2004, 4, 1921-1929.	1.4	13
123	Oncogene Suppression by Small Interfering RNAs. Current Pharmaceutical Biotechnology, 2004, 5, 349-354.	0.9	10
124	Suppression of MLL-AF4 by Small Interfering RNAs Inhibits Proliferation and Induces Apoptosis in T(4;11)-Positive SEM Cells.. Blood, 2004, 104, 4433-4433.	0.6	0
125	Decrease of Malignant Potential of t(8;21) Positive Cells after Stable Expression of RUNX-CBFA2T1-Specific Small Interfering RNA.. Blood, 2004, 104, 4274-4274.	0.6	0
126	The Apparent Uptake of Fluorescently Labeled siRNAs by Electroporated Cells Depends on the Fluorochrome. Oligonucleotides, 2003, 13, 375-380.	2.7	25

#	Article	IF	Citations
127	Gene Silencing by RNAi in Mammalian Cells. Current Protocols in Molecular Biology, 2003, 62, Unit 26.2.	2.9	6
128	AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood, 2003, 101, 3157-3163.	0.6	160
129	Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood, 2003, 101, 1566-1569.	0.6	251
130	Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells. Journal of Cell Biology, 2002, 156, 737-750.	2.3	176
131	Analysis of the Nuclear Distribution of the Translocation t(8;21)-Derived Fusion Protein AML1/ETO by Confocal Laser Scanning Microscopy. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 401-408.	1.8	3
132	Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes. FEBS Journal, 2001, 268, 3550-3557.	0.2	8
133	Detection and quantification ofCBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes and Cancer, 2001, 30, 342-348.	1.5	35
134	Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia, 2000, 14, 329-335.	3.3	59
135	Evaluation of the Effectiveness of DNA-Binding Drugs To Inhibit Transcription Using the c-fos Serum Response Element as a Target. Biochemistry, 2000, 39, 12262-12273.	1.2	25
136	MAPKAP Kinase 2 Phosphorylates Serum Response Factor in Vitro and in Vivo. Journal of Biological Chemistry, 1999, 274, 14434-14443.	1.6	154
137	Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. British Journal of Haematology, 1999, 107, 80-85.	1.2	58
138	RNase H-independent antisense activity of oligonucleotide N3'->P5' phosphoramidates. Nucleic Acids Research, 1997, 25, 776-780.	6.5	72
139	Ribozyme in der molekularen Medizin. , 1997, , 242-265.		0
140	A Hammerhead Ribozyme Cleaves Its Target RNA During RNA Preparation. Oligonucleotides, 1996, 6, 141-144.	4.4	12
141	Rapid PCR Method for Site-Directed Mutagenesis on Double-Stranded Plasmid DNA. BioTechniques, 1996, 20, 44-46.	0.8	12
142	Sequence Requirements of ATF2 and CREB Binding to the Human T-Cell Leukemia Virus Type 1 LTR R Region. Virology, 1996, 218, 362-371.	1.1	15
143	Adenovirus-Mediated Interferon-Î³ Transfer Inhibits Growth of Transplanted HTLV-1 Tax Tumors in Mice. Human Gene Therapy, 1996, 7, 471-477.	1.4	9
144	HAM/TSP and ATL: Persistent paradoxes and new hypotheses. Journal of NeuroVirology, 1996, 2, 60-69.	1.0	4

#	Article	IF	Citations
145	Correlation of Activity with Stability of Chemically Modified Ribozymes in Nuclei Suspension. Oligonucleotides, 1996, 6, 111-118.	4.4	19
146	Binding and Functional Effects of Transcriptional Factor Sp1 on the Murine Interleukin-6 Promotor. Journal of Biological Chemistry, 1996, 271, 7330-7335.	1.6	44
147	Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Research, 1995, 23, 2223-2228.	6.5	52
148	A new affinity purification procedure for DNA-binding proteins using bromoacetyl agarose. Nucleic Acids Research, 1995, 23, 2344-2345.	6.5	12
149	Application of antisense technology to therapeutics. Trends in Molecular Medicine, 1995, 1, 128-133.	2.6	26
150	Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells.. Journal of Clinical Investigation, 1995, 96, 1548-1555.	3.9	117
151	High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates.. Journal of Biological Chemistry, 1994, 269, 2131-2138.	1.6	149
152	Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.. Journal of Biological Chemistry, 1994, 269, 26801-26805.	1.6	293
153	Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. Journal of Biological Chemistry, 1994, 269, 26801-5.	1.6	217
154	High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates. Journal of Biological Chemistry, 1994, 269, 2131-8.	1.6	115
155	Chemically modified RNA: approaches and applications.. FASEB Journal, 1993, 7, 90-96.	0.2	94
156	Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. Journal of Biological Chemistry, 1992, 267, 1904-9.	1.6	117
157	Inhibition of the Reverse Transcriptase of HIV-1 by 3â€²-Azidothymidine Triphosphate and 3â€²-Azido-oligothymidylate. Nucleosides & Nucleotides, 1991, 10, 535-536.	0.5	8
158	Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate. FEBS Journal, 1990, 192, 621-625.	0.2	32
159	Gene Silencing Methods for Mammalian Cells: Application of Synthetic Short Interfering RNAs. , 0, , 896-909.		0